S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
S&P 500   4,286.59 (+0.10%)
DOW   33,652.91 (-0.33%)
QQQ   356.22 (+0.44%)
AAPL   183.33 (+1.32%)
MSFT   337.67 (+0.68%)
META   273.05 (+0.16%)
GOOGL   126.73 (+1.65%)
AMZN   124.73 (+0.39%)
TSLA   217.90 (+1.84%)
NVDA   389.90 (-0.86%)
NIO   7.74 (+2.38%)
BABA   83.98 (-0.34%)
AMD   118.22 (+0.31%)
T   15.32 (+0.72%)
F   12.63 (+1.94%)
MU   68.00 (-1.69%)
CGC   0.79 (-4.50%)
GE   104.62 (-1.12%)
DIS   89.83 (-1.04%)
AMC   4.61 (+1.32%)
PFE   38.78 (+1.09%)
PYPL   64.40 (+0.69%)
NFLX   409.97 (+2.37%)
NASDAQ:CRME

Cardiome Pharma (CRME) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.30
▼
$2.45
50-Day Range
N/A
52-Week Range
$1.29
▼
$4.84
Volume
90,444 shs
Average Volume
135,322 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media

CRME stock logo

About Cardiome Pharma (NASDAQ:CRME) Stock

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

CRME Stock News Headlines

March 25, 2023 | marketwatch.com
Expert Analysis on Pharmaceutical Rubber Stoppers Market by 2023-2030
February 17, 2023 | msn.com
Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
June 5, 2023 | Edge On The Street (Ad)
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
February 12, 2023 | msn.com
Pharmacy Career Conference returned in its 4th edition to assist and inspire pharmacy students and industry professionals
February 1, 2023 | msn.com
Pharma sector growth healthy after Covid too
December 29, 2022 | cbsnews.com
DOJ sues pharma giant AmerisourceBergen Corp. for allegedly helping to fuel the opioid epidemic
November 2, 2022 | marketwatch.com
Acute Coronary Syndrome Therapeutics Market Size in Pharma & Healthcare Sector is Growing Quickly with Analysis by Top Key players till 2028
October 20, 2022 | yahoo.com
Pharmaceutical Fine Chemicals Category Is Projected to Grow at a CAGR of 5.86% by 2026, SpendEdge Reports
June 5, 2023 | Edge On The Street (Ad)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
October 13, 2022 | finance.yahoo.com
Jenny Sundqvist new CEO of InDex Pharmaceuticals
September 28, 2022 | benzinga.com
1SOMAÍ Pharmaceuticals Opens Medical Cannabis Manufacturing Facility In Portugal
September 13, 2022 | msn.com
NLEM 2022 | Govt releases new list of 384 essential medicines; 34 drugs added, 26 dropped
September 13, 2022 | msn.com
Macleods Pharmaceuticals defers big-bang listing plans; will PE funds step in now?
August 30, 2022 | marketwatch.com
Cardiac Rhythm Management Devices Market [4.5% CAGR] 2022 Industry Research Analysis Opportunities Key Players Analysis And Forecast By 2028
October 26, 2021 | finance.yahoo.com
Cardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal Financing
June 21, 2020 | www.bloomberg.com
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results
June 17, 2020 | www.bloomberg.com
Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies
June 2, 2020 | www.bloomberg.com
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa
May 23, 2020 | www.bloomberg.com
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
May 21, 2020 | www.bloomberg.com
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
March 28, 2020 | www.bloomberg.com
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
February 6, 2020 | finance.yahoo.com
Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
November 28, 2019 | www.thestreet.com
Cardiome Pharma Corp. (CRME): Today's Featured Health Care Loser
See More Headlines


CRME Company Calendar

Last Earnings
5/15/2018
Today
6/05/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRME
CUSIP
N/A
CIK
1036141
Web
www.cardiome.com
Phone
604-677-6905
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A

Key Executives

  • Dr. William L. Hunter (Age 55)
    Pres, CEO & Director
  • Ms. Sheila M. Grant MBA
    Chief Operating Officer
  • Mr. David D. McMasters (Age 59)
    Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer
  • Mr. Justin A. Renz (Age 46)
    Chief Financial Officer

Key Competitors

View All Competitors













CRME Stock - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) issued its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), C3.ai (AI) and Government Properties Income Trust (GOV).

What is Cardiome Pharma's stock symbol?

Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."

What is Cardiome Pharma's stock price today?

One share of CRME stock can currently be purchased for approximately $2.33.

How can I contact Cardiome Pharma?

Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The official website for the company is www.cardiome.com. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at ir@cardiome.com.

This page (NASDAQ:CRME) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -